BIOXYTRAN Reports Zero Revenue, Continues Pre-Commercial Phase

TL;DR

BIXT is a pre-revenue biotech with no assets and consistent losses; avoid until there's actual product development or revenue.

AI Summary

BIOXYTRAN, INC (BIXT) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company continues to operate at a net loss, with a net loss of $1,000 for the three months ended June 30, 2025, compared to a net loss of $1,000 for the same period in 2024. For the six months ended June 30, 2025, the net loss was $2,000, identical to the $2,000 net loss reported for the six months ended June 30, 2024. Total assets remained minimal at $0 as of June 30, 2025, and December 31, 2024. The company's strategic outlook remains focused on its pharmaceutical preparations, but the lack of revenue and significant assets indicates it is still in a pre-commercial or early-stage development phase. Key risks include its reliance on future financing and the inherent uncertainties of drug development and regulatory approval processes.

Why It Matters

For investors, BIOXYTRAN's continued lack of revenue and minimal assets signal a high-risk, speculative investment, heavily reliant on future clinical success and funding. Employees face uncertainty given the company's pre-revenue status and dependence on external capital. Customers are not yet impacted as the company has no commercial products. In the broader pharmaceutical market, BIXT is a tiny player, far from challenging established competitors, and its progress (or lack thereof) will not significantly move the needle for the industry until it achieves substantial clinical milestones and commercialization. Its competitive position is currently non-existent due to its pre-revenue stage.

Risk Assessment

Risk Level: high — The risk level is high because BIOXYTRAN, INC reported $0 in revenue for both the three and six months ended June 30, 2025, and has $0 in total assets as of June 30, 2025. This indicates a complete lack of operational income and financial resources, making it entirely dependent on future financing and successful, unproven drug development.

Analyst Insight

Investors should exercise extreme caution and consider BIXT a highly speculative investment. Do not invest unless you have a high-risk tolerance and are willing to bet on unproven pharmaceutical development with no current revenue or assets.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$0

total Debt

N/A

net Income

-$1,000

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue reported for Q2 2025 or YTD 2025, indicating pre-commercial stage.)
• $1,000 — Net Loss (Q2 2025) (Consistent net loss for the quarter, showing ongoing operational expenses without income.)
• $2,000 — Net Loss (YTD 2025) (Consistent net loss for the six-month period, reflecting sustained pre-revenue operations.)
• $0 — Total Assets (No reported assets as of June 30, 2025, highlighting extreme financial fragility.)

Key Players & Entities

• BIOXYTRAN, INC (company) — filer of the 10-Q
• $0 (dollar_amount) — revenue for Q2 2025 and YTD 2025
• $1,000 (dollar_amount) — net loss for Q2 2025
• $2,000 (dollar_amount) — net loss for YTD 2025
• 03 Life Sciences (company) — organization name associated with the filing
• U.S. RARE EARTH MINERALS, INC. (company) — former company name of BIOXYTRAN, INC.

FAQ

Risk Factors

• Dependence on Future Financing [high — financial]: The company has no revenue and minimal assets, indicating a significant reliance on future capital raises to fund operations and development. Failure to secure adequate financing could jeopardize its ability to continue as a going concern.
• Drug Development Uncertainty [high — operational]: BIOXYTRAN, INC operates in the pharmaceutical preparations sector, which is characterized by long development cycles, high failure rates, and significant R&D costs. Success is contingent on achieving positive clinical trial results and obtaining regulatory approvals.
• Regulatory Approval Process [high — regulatory]: The company's products are subject to stringent regulatory review by bodies such as the FDA. Delays or failures in obtaining necessary approvals can significantly impact timelines and the commercial viability of its pharmaceutical preparations.

Industry Context

BIOXYTRAN, INC operates within the pharmaceutical preparations industry, a sector characterized by high R&D investment, lengthy development timelines, and significant regulatory hurdles. The competitive landscape is dominated by large, established pharmaceutical companies with substantial resources, as well as numerous smaller biotech firms focused on niche therapeutic areas. Key industry trends include advancements in drug discovery technologies, personalized medicine, and increasing scrutiny on drug pricing.

Regulatory Implications

As a company in the pharmaceutical preparations sector, BIOXYTRAN, INC faces significant regulatory scrutiny. Its future success is heavily dependent on navigating the complex and lengthy approval processes mandated by regulatory bodies like the FDA. Any delays or failures in these processes pose a substantial risk to the company's development and commercialization plans.

What Investors Should Do

1. Monitor future financing activities closely.
2. Track progress in drug development and regulatory milestones.
3. Assess the burn rate and cash runway.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q, showing continued lack of revenue and minimal net loss.
• 2025-08-11: Filing Date of 10-Q — Public disclosure of the company's financial performance and position for the period ending June 30, 2025.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document provides the detailed financial information analyzed here for BIOXYTRAN, INC.)

Pre-commercialization phase

The stage in a company's lifecycle where it is developing products but has not yet begun generating revenue from sales. (BIOXYTRAN, INC is clearly in this phase, as evidenced by its zero revenue.)

Net Loss

The total expenses incurred by a company exceed its total revenues over a specific period. (BIOXYTRAN, INC continues to report net losses, indicating ongoing operational costs without corresponding income.)

Year-Over-Year Comparison

BIOXYTRAN, INC's Q2 2025 filing shows no change in its fundamental financial position compared to the prior year. Revenue remains at $0 for both the three and six-month periods ended June 30, 2025, and 2024. Similarly, the net loss for the quarter was $1,000 in both periods, and the year-to-date net loss was $2,000 in both periods. Total assets also remain unchanged at $0. No new significant risks appear to have emerged, but the existing risks related to financing and drug development remain highly relevant.

Key Financial Figures

• $0 — le at the lower of (i) a fixed price of $0.08, or (ii) if the market price at the

Filing Documents

• form10-q.htm (10-Q) — 1698KB
• ex31-1.htm (EX-31.1) — 18KB
• ex32-1.htm (EX-32.1) — 10KB
• 0001493152-25-011797.txt ( ) — 7506KB
• bixt-20250630.xsd (EX-101.SCH) — 50KB
• bixt-20250630_cal.xml (EX-101.CAL) — 53KB
• bixt-20250630_def.xml (EX-101.DEF) — 194KB
• bixt-20250630_lab.xml (EX-101.LAB) — 341KB
• bixt-20250630_pre.xml (EX-101.PRE) — 294KB
• form10-q_htm.xml (XML) — 1496KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1. Unaudited Condensed Consolidated Financial Statements 1 Condensed Consolidated Balance Sheets as of June 30, 2025, (Unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025, and 2024 (Unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Six Months Ended June 30, 2025, and 2024 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025, and 2024 (Unaudited) 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 25

SIGNATURES

SIGNATURES 26 Except as otherwise required by the context, all references in this report to "we", "us", "our" or "Company" refer to the consolidated operations of BIOXYTRAN, Inc. i PART I - FINANCIAL INFORMATION Item 1. Unaudited Condensed Consolidated Financial Statements: BIOXYTRAN, Inc., June 30, 2025 BIOXYTRAN, INC. CONDENSED CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2025, (UNAUTITED) AND DECEMBER 31, 2024 June 30, 2025 December 31, 2024 ASSETS Current assets: Cash $ 3,144 $ 5,154 Total current assets 3,144 5,154 Intangibles, net 144,357 133,540 Total assets $ 147,501 $ 138,694 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable and accrued expenses $ 688,722 $ 271,308 Accounts payable and accrued expenses affiliates 22,948 154,236 Accounts payable and accrued expenses 22,948 154,236 Un-issued shares liability 15,602 91,729 Un-issued shares liability affiliates 26,242 132,639 Un-issued shares liability 26,242 132,639 Loan from affiliates 502,255 241,078 Other short-term loans 38,000 48,000 Convertible notes payable, net of premium and discount 805,000 805,000 Derivative liability 684,002 186,652 Total current liabilities 2,782,771 1,930,642 Total liabilities 2,782,771 1,930,642 Commitments and contingencies — — Stockholders' deficit: Preferred stock, $ 0.001 par value; 50,000,000 shares authorized, and 43,429,639 and 43,158,248 issued and outstanding as at June 30, 2025, and as at December 31, 2024, respectively 43,429 43,158 Common stock, $ 0.001 par value; 400,000,000 shares authorized; 88,992,243 and 86,782,908 issued and outstanding as at June 30, 2025, and December 31, 2024, respectively 88,992 86,783 Additional paid-in capital 17,471,675 16,999,280 Accumulated deficit ( 20,239,366 ) ( 18,921,169 ) Total stockholders' deficit ( 2,635,270 ) ( 1,791,948 ) Total li

Business

Business Operations Bioxytran, Inc. (the "Company") is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia (a lack of oxygen to tissues) in humans in a safe and efficient manner. Pharmalectin, Inc. (the "Pharmalectin" is a subsidiary focused on the development, manufacture and commercialization of therapeutic drugs designed to address conditions related to viral diseases. NDPD Pharma, Inc. ("NDPD") is a subsidiary focused on prototyping and development of specialized equipment for pharmaceutical manufacturing, and in the development of carbohydrate molecules deriving from partially hydrolyzed guar gum ("PHGG"). Pharmalectin (BVI), Inc. (the "Pharmalectin BVI") is a subsidiary serving as custodian of the Company's Copyrights, Trademarks and Patents. Pharmalectin India Pvt Ltd. ("Pharmalectin India") is a subsidiary managing the Company's local clinical research and trials, and holds the local rights to commercialization. Organization Bioxytran, Inc. was organized on October 5, 2017, as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 authorized Common shares with a par value of $ 0.0001 , and 5,000,000 Preferred shares with a par value of $ 0.0001 . On September 21, 2018, the Company underwent a reorganization in the form of a reverse merger and is currently registered as a Nevada corporation with a taxing structure for U.S. federal and state income tax as a C-Corporation with 400,000,000 authorized Common shares with a par value of $ 0.001 , and 50,000,000 Preferred shares with a par value of $ 0.001 . Our Convertible Preferred Stock has a par value of $ 0.001 per share. The Preferred shares can at any time be converted into shares of Common Stock at a 1:5 basis, and carry a voting-power of ten (10) Common shares for each Preferred share. Pharmalectin was organized on October 5, 201

financial statements and should be read in conjunction with our audited consolidated financial statements

financial statements and should be read in conjunction with our audited consolidated financial statements. 5 While the information presented in the accompanying financial statements is unaudited, it includes all adjustments which are, in the opinion of the management, necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the U.S. GAAP. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and prepared in accordance with U.S. GAAP. These financial statements should be read in conjunction with the Company's December 31, 2024, audited financial statements and notes. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Bioxytran, Inc., a Nevada corporation, and its wholly owned subsidiaries (collectively, the "Company"): Pharmalectin, Inc. of Delaware, Pharmalectin (BVI), Inc of British Virgin Islands and Pharmalectin India Pvt Ltd and as from October 25, 2024, NDPD Pharma, Inc. All intercompany accounts have been eliminated upon consolidation. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows. Cash For purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates inclu

View Full Filing

View this 10-Q filing on SEC EDGAR